Bayer Aktiengesellschaft (BAYZF)
| Market Cap | 48.77B |
| Revenue (ttm) | 53.81B |
| Net Income (ttm) | -232.31M |
| Shares Out | n/a |
| EPS (ttm) | -0.24 |
| PE Ratio | n/a |
| Forward PE | 8.36 |
| Dividend | 0.13 (0.25%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 1,087 |
| Average Volume | 4,273 |
| Open | 49.00 |
| Previous Close | 50.06 |
| Day's Range | 49.00 - 49.63 |
| 52-Week Range | 20.99 - 58.33 |
| Beta | 0.97 |
| RSI | 41.77 |
| Earnings Date | Mar 4, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.
Financial numbers in EUR Financial StatementsNews
Bayer (BAYRY) Reports Promising Phase 1 Results for Targeted Cancer Therapy
Bayer (BAYRY) Reports Promising Phase 1 Results for Targeted Cancer Therapy
Bayer releases promising early-stage data on prostate cancer therapy
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
BERLIN--(BUSINESS WIRE)--Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary ef...
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of 225Ac-PSMA-Tril...
Bayer's (BAYRY) Xofigo Combo Shows 24% Survival Benefit in mCRPC Trial
Bayer's (BAYRY) Xofigo Combo Shows 24% Survival Benefit in mCRPC Trial
Bayer says Xofigo/Xtandi combo shows overall survival benefit in prostate cancer
Bayer Xofigo + Pfizer/Astellas Xtandi improved survival in mCRPC with bone metastases. Read more here.
Bayer's XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer's XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases.
Bayer’s XOFIGO (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases
Final results from the pivotal investigational Phase III PEACE-3 trial demonstrate that first-line treatment with XOFIGO (radium-223 dichloride) in combination with enzalutamide, an androgen receptor ...
Lawyers for US cancer sufferers challenge Bayer’s $7.25bn Roundup settlement deal
Proposed settlement would pay users of glyphosate-based weedkiller who have non-Hodgkin lymphoma $10,000 to $165,000 A group of 14 law firms representing nearly 20,000 plaintiffs is seeking to interve...
Some roundup plaintiffs seek to delay preliminary approval of proposed $7.25 bln bayer settlement, court filing shows
Law firms representing nearly 20,000 people who sued Bayer over alleged injuries from its Roundup weedkiller urged a Missouri judge on Wednesday to delay reviewing the German company's proposed $7.25 ...
Bayer sues Johnson & Johnson over prostate cancer drug claims
Bayer (BAYRY) sued Johnson & Johnson (JNJ) on Monday, alleging a false advertising campaign for its prostate cancer drug Erleada.
Bayer Sues J&J Over Prostate Cancer Treatment Promotion Dispute
(RTTNews) - German pharmaceutical and life sciences major Bayer AG (BAYRY.PK, BAYZF.PK) announced that it has filed false advertising suit against Johnson & Johnson or J&J (JNJ) and Janssen Biotech, I...
Bayer files lawsuit against Johnson & Johnson, Janssen Biotech
German pharmaceutical company Bayer said on Monday that it had filed a lawsuit in a New York court against Johnson & Johnson and Janssen Biotech Inc related to its Nubeqa prostate cancer drug.
Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that it has filed suit against Johnson & Johnson (J&J) and Janssen Biotech, Inc. in the United States District Court for the Southern District of...
Bayer Alleges J&J’s Claims Regarding NUBEQA are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA
Bayer announced today that it has filed suit against Johnson & Johnson (J&J) and Janssen Biotech, Inc. in the United States District Court for the Southern District of New York. The suit follows J&J’s...
Bayer, John Deere Further Integrate FieldView and Operations Center to Improve Customer Experience for 2026 Season
ST. LOUIS--(BUSINESS WIRE)--Bayer and John Deere today announced a new capability that simplifies how U.S. farmers and advisors move from agronomic decisions to precise execution in the field. Beginni...
Voyageur Pharmaceuticals Announces Collaboration with Bayer
Calgary, Alberta, Canada – TheNewswire – February 23, 2026 - Voyageur Pharmaceuticals Ltd. ( TSXV:VM) ( OTC Pink:VYYRF) (" Voyageur " or the " Company ") a Canadian developer of pharmaceutical-grade ...
Notable healthcare headlines for the week: J&J, Masimo and Bayer in focus
Bayer proposes $7.25 billion Roundup settlement as Supreme Court case looms
A new $7.25 billion settlement between Bayer and a group of cancer patients could wrap up a huge wave of lawsuits against the company over allegations that it didn't warn consumers about cancer risks ...
Biodexa Licenses Phase 1-Ready Drug Candidate From Otsuka For Rare Stomach Cancer
Zinger Key Point: MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical-stage bi...
Bayer: glyphosate shortages not expected outside the US after executive order
The U.S. President's executive order invoking the Defense Production Act to ensure U.S. supply of glyphosate underscores U.S. farmers' needs to have access to the herbicide, Bayer said on Thursday, ad...
Trump Invokes Defense Act For Monsanto Chemicals: Bayer, Agribusiness ETFs In Focus On New Critical Mineral Status For Phosphorus
In a major move to solidify the America First industrial strategy, President Donald Trump signed an executive order on Feb. 18, mobilizing the Defense Production Act (DPA) to secure the domestic suppl...
Explainer: Will Bayer's proposed $7.25 billion Roundup deal bring legal closure?
Bayer's Monsanto unit has proposed a $7.25 billion nationwide class settlement to resolve both current and future lawsuits alleging that its Roundup weedkiller caused cancer, billing it as a long-awai...
Bayer Falls 8.4% On $7.25 Billion Plan
Bayer Falls 8.4% On $7.25 Billion Plan